All In Biotech

Drug Trial Radar · NCT03277248

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

Phase III: UbLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)

Last checked: Nov 20, 2026Latest source record: Dec 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 545 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

545

Actual

Start

Aug 25, 2017

Primary completion

Aug 4, 2020

Study completion Nov 12, 2020

Sponsor

Lead sponsor
TG Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 11, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/IV placebo.

Conditions

  • Relapsing Multiple Sclerosis (RMS)

Interventions

  • UblituximabBiological

    Administered as an IV infusion.

  • TeriflunomideDrug

    Film coated tablets administered orally.

  • Oral PlaceboDrug

    Administered orally.

  • IV PlaceboDrug

    Administered as an IV Infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate (ARR)Time frame: Up to 96 weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • TG Therapeutics RMS Investigational Trial site

    Phoenix, Arizona

  • TG Therapeutics RMS Investigational Trial Site

    Aurora, Colorado

  • TG Therapeutics RMS Investigational Trial Site

    Tampa, Florida

  • TG Therapeutics RMS Investigational Trial Site

    Lexington, Kentucky

  • TG Therapeutics RMS Investigational Trial Site

    Chesterfield, Missouri

  • TG Therapeutics RMS Investigational Trial Site

    Las Vegas, Nevada

  • TG Therapeutics RMS Investigational Trial Site

    Teaneck, New Jersey

  • TG Therapeutics RMS Investigational Trial Site

    Albuquerque, New Mexico

  • TG Therapeutics RMS Investigational Trial Site

    Patchogue, New York

  • TG Therapeutics RMS Investigational Trial site

    Columbus, Ohio

  • TG Therapeutics RMS Investigational Trial Site

    Pittsburgh, Pennsylvania

  • TG Therapeutics RMS Investigational Trial site

    San Antonio, Texas

  • TG Therapeutics RMS Investigational Trial site

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.